Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study | Zendy

Gábor G. Kovács | Zendy; Antonio Wachtel | Zendy; Е В Башарова | Zendy; Tulla Spinelli | Zendy; Nicolas Pierre | Zendy; Edita Kabíčková | Zendy

Open Access

Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study

Author(s) -

Gábor G. Kovács,

Antonio Wachtel,

Е В Башарова,

Tulla Spinelli,

Nicolas Pierre,

Edita Kabíčková

Publication year - 2017

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2017-0189

Subject(s) - palonosetron , ondansetron , medicine , nausea , vomiting , chemotherapy , chemotherapy induced nausea and vomiting , adverse effect , anesthesia , oncology , antiemetic

Aim: To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC). Patients & methods: Patients were randomly assigned to 10, 20 μg/kg palonosetron or 3 × 150 μg/kg ondansetron for up to four cycles of HEC/MEC. Results: In all on-study chemotherapy cycles, complete response rates were higher in patients in the 20 μg/kg palonosetron group than the ondansetron group. Treatment-emergent adverse events were comparable between the palonosetron 20 μg/kg and ondansetron groups. Conclusion: Over four cycles of HEC/MEC, 20 μg/kg palonosetron was an efficacious and safe treatment for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research